A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS)

OBJECTIVE: Up to 87% of uterine leiomyosarcomas have estrogen receptor positivity. There are no effective adjuvant therapies for LMS. The objective of this study was to determine the efficacy of letrozole in patients with newly diagnosed uterine leiomyosarcoma (uLMS). The primary endpoint of this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Slomovitz, Brian M., Taub, Michael C., Huang, Marilyn, Levenback, Charles, Coleman, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260388/
https://www.ncbi.nlm.nih.gov/pubmed/30519622
http://dx.doi.org/10.1016/j.gore.2018.11.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260388/
https://www.ncbi.nlm.nih.gov/pubmed/30519622
http://dx.doi.org/10.1016/j.gore.2018.11.001

Ejemplares similares